1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc.

BUGVF
Primo Nutraceuticals Inc.US flagOther OTC
0.00
USD
-NaN
- -
26.00Market Cap
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.23
-1.17
-0.46
Free Cash Flow per Basic Share
-0.01
-0.01
-0.34
-0.31
-0.15
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-0.01
-0.02
0.02
-0.14
0.06
Tangible Book Value per Share
-0.01
-0.01
0.05
-0.12
0.07
Basic Weighted Avg Shares
5
5
3
4
8
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
-5
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
Working Capital
- -
- -
-2
-3
-3
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-736.81

Capital Structure

FRC

•

in mil. unless spec.
Oct'20
Jan'20
Apr'20
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
10
Market Capitalization
8
10
2

Working Capital

FRC

•

in mil. unless spec.
Oct'20
Jan'20
Apr'20
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
3
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-413.68%
Free Cash Flow
- -
- -
15.34%
Net Income, GAAP
- -
- -
554.07%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
-0.02
-0.03
- -
-0.23
2019
-0.09
-0.07
-0.4
- -
-1.17
2020
-0.08
-0.01
-0.04
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Richard Cindric
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
890 West Pender Street Vancouver BC Canada V6C 1J9
IPO Date
Apr 22, 2019
Website
primonutraceuticals.com
Similar Companies
Cresco Labs Inc. (CL.CN)
Shilpa Medicare Limited (SHILPAMED.BO)
Decibel Cannabis Company Inc. (DB.V)
Torii Pharmaceutical Co., Ltd. (4551.T)
Transnational Cannabis Ltd. (TRCNF)
RPG Life Sciences Limited (RPGLIFE.BO)
Business
Primo Nutraceuticals Inc. owns and develops commercial real estate properties and turnkey cultivation facilities for the cannabis cultivation sector; offers seed-to-sale services, including infrastructure, equipment leases, property management, consulting, advisory services, yield optimization technology, recycling, and soil remediation; provides proprietary formulas for cannabis edibles, topicals, and tinctures; and develops premium hemp-derived consumer products such as CBD-blended tinctures for anxiety, energy, and sleep under brands like Thrive Wellness and Grounded CBD. The Vancouver, British Columbia-based company, founded in 2014, operates primarily in Canada with additional activities in the United States, including a hemp production and processing license through subsidiary Worm Casting Farms Inc. on 10 acres in Oregon and a fully constructed 10,000-square-foot growing facility in Washington state with an existing tenant and option for six more acres. Recent developments include a 2020 name change from Bougainville Ventures Inc., a letter of intent to acquire 25% of Beauty Kitchen Canada, a binding letter of intent in November 2020 to acquire assets of Full Spectrum Biosciences Inc., and a definitive agreement with former MLB executive Dan Duquette to capitalize on receipt of a Medical Device Establishment License.